Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Proof of Biological Activity of SAR100842 in Systemic Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: July 24, 2012
Last updated: February 26, 2016
Last verified: February 2016

Primary Objective:

- To evaluate safety and tolerability of 8-week oral administration of SAR100842 in patients with diffuse cutaneous systemic sclerosis.

Secondary Objectives:

  • To evaluate the pharmacodynamic effect of SAR100842 in patients with systemic sclerosis as measured by disease related biomarkers and Lysophosphatidic acid (LPA) receptor signaling markers in blood and skin;
  • To explore the effect of SAR100842 on skin thickness in patients with systemic sclerosis as measured by the modified Rodnan Skin Score (mRSS);
  • To explore the effect of SAR100842 on quality of life as measured by the Scleroderma Modified Health Assessment Questionnaire (SHAQ);
  • To document long term safety of SAR100842 during the extension part.

Condition Intervention Phase
Systemic Sclerosis
Drug: SAR100842
Drug: Placebo (for SAR100842)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Safety and tolerability during the 8 week treatment period (core part): Number of patients reporting adverse events [ Time Frame: Up to 8 weeks ]

Secondary Outcome Measures:
  • Change from baseline to Week 8 in biomarkers obtained from blood and skin [ Time Frame: Day 1 and Week 8 (core part) ]
  • Change from baseline to Week 8 in Modified Rodnan Skin Score (mRSS) [ Time Frame: Day 1 and Week 8 (core part) ]
  • Change from baseline to Week 8 in Scleroderma Health Assessment Questionnaire (SHAQ) score [ Time Frame: Day 1 and Week 8 (core part) ]

Enrollment: 32
Study Start Date: January 2013
Study Completion Date: April 2014
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SAR100842

Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks

Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks

Drug: SAR100842

Pharmaceutical form: tablets

Route of administration: oral

Placebo Comparator: Placebo

Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks

Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks

Drug: SAR100842

Pharmaceutical form: tablets

Route of administration: oral

Drug: Placebo (for SAR100842)

Pharmaceutical form: tablets

Route of administration: oral

Detailed Description:

Core part: randomized, double-blind, placebo-controlled study - 8-week treatment Extension part for participants completing the core part: Open label non-controlled study - 16-week treatment

Each patient's participation in the study will be approximately 13 or 33 weeks depending on their participation in the extension part: up to 2 weeks of screening, 8 weeks of treatment in the core part, 1 to 30 days wash-out between core part and extension part , 16 weeks of treatment in the extension part and 3 weeks of follow up.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria :

- Patients who meet the American College of Rheumatology (ACR) criteria for systemic sclerosis with diffuse cutaneous involvement and <36 months since the onset of the first systemic sclerosis manifestation other than Raynaud's phenomenon and have a Modified Rodnan Skin Score (mRSS) ≥ 15 and an area of definite involvement of the dorsal forearm that is considered amenable to repeated 4mm skin biopsies.

Exclusion criteria:

  1. Patients with high dose or unstable low dose immunosuppressive drugs, cytotoxic, anti-fibrotic or glucocorticoids drugs at least 4 weeks prior to screening
  2. Serum creatinine > 2.0 mg/dL
  3. Gastrointestinal involvement preventing oral administration of study drug
  4. Severe cardiac and/or pulmonary disease

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01651143

United States, Arizona
Investigational Site Number 840006
Scottsdale, Arizona, United States, 85259-5499
United States, District of Columbia
Investigational Site Number 840003
Washington, District of Columbia, United States, 20007
United States, Maryland
Investigational Site Number 840004
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Investigational Site Number 840001
Boston, Massachusetts, United States, 02118
United States, Michigan
Investigational Site Number 840002
Ann Arbor, Michigan, United States, 48106
United States, New Jersey
Investigational Site Number 840007
New Brunswick, New Jersey, United States, 08903
United States, Pennsylvania
Investigational Site Number 840008
Pittsburgh, Pennsylvania, United States, 15213
Investigational Site Number 250003
Lille, France, 59037
Investigational Site Number 250001
Paris Cedex 14, France, 75679
Investigational Site Number 380001
Milano, Italy, 20122
Investigational Site Number 756001
Zürich, Switzerland, 8091
United Kingdom
Investigational Site Number 826001
London, United Kingdom
Investigational Site Number 826002
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT01651143     History of Changes
Other Study ID Numbers: ACT12339
2012-001369-34 ( EudraCT Number )
U1111-1127-2854 ( Other Identifier: UTN )
Study First Received: July 24, 2012
Last Updated: February 26, 2016

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases processed this record on May 25, 2017